Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Targeting deficient DNA damage repair in gastric cancer.

Thumbnail
View/Open
Accepted version (869.4Kb)
Date
2016-09
ICR Author
Cunningham, David
Starling, Naureen
Author
Young, K
Starling, N
Cunningham, D
Type
Journal Article
Metadata
Show full item record
Abstract
Introduction Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has been identified as a tumour where a subgroup of patients demonstrates deficiencies in the homologous recombination pathway providing a potential novel treatment approach for this poor prognosis disease.Area covered This review provides an overview of DNA damage repair and how this has been targeted to date in other tumour types exploiting the concept of synthetic lethality. This is followed by a discussion of how deficiencies in homologous recombination may be identified across tumour types and on recent progress in targeting DNA repair deficiencies in gastric cancer.Expert opinion Gastric cancer remains a difficult malignancy to treat and the possibility of targeting deficient DNA repair in a subgroup of patients is an exciting prospect. Future combinations with immunotherapy and radiotherapy are appealing and appear to have a sound biological rationale. However, much work remains to be done to understand the significance of the genetic and epigenetic alterations involved, to elucidate the optimum predictive signatures or biomarkers and to consider means of overcoming treatment resistance.
URI
https://repository.icr.ac.uk/handle/internal/529
DOI
https://doi.org/10.1080/14656566.2016.1217992
Collections
  • Clinical Studies
Subject
Humans
Stomach Neoplasms
DNA Damage
DNA Repair
Homologous Recombination
Research team
Gastrointestinal Cancers Clinical Trials
Medicine (RMH Smith Cunningham)
Language
eng
License start date
2016-09
Citation
Expert opinion on pharmacotherapy, 2016, 17 (13), pp. 1757 - 1766

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.